Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-09-16FDA Approved: CELECOXIB — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for celecoxib (generic) under ANDA204197.
-
FDA approval · 2016-09-14FDA Approved: CELECOXIB — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for CELECOXIB from Aurobindo Pharma Limited (ANDA206827). This notice confirms the supplemental appr…
-
FDA label_change · 2016-09-13FDA Approved: CELECOXIB — Supplemental Application (Cipla USA Inc.)
FDA Approved: CELECOXIB — Supplemental Application (Cipla USA Inc.) indicating a labeling modification related to celecoxib.
-
FDA approval · 2016-09-01FDA Approved: ZYBIC — Supplemental Application (Redmont Pharmaceuticals, LLC)
The FDA approved a supplemental application for ZYBIC (meloxicam) filed by Redmont Pharmaceuticals, LLC.
-
CLINICAL_TRIALS research · 2016-09-01Clinical Trial Update: C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France
The C.O.R.P.U.S. observational cohort study of adult and child inflammatory arthritis in France has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-08-15FDA Approved: MELOXICAM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for MELOXICAM from Zydus Pharmaceuticals USA Inc., granting approval to market generic meloxicam in …
-
CLINICAL_TRIALS research · 2016-07-26Clinical Trial Update: Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases [NA]
This entry provides an update on a pediatric clinical trial examining cellular and molecular adaptations to exercise-induced inflammatory re…
-
CLINICAL_TRIALS trial_result · 2016-07-04Clinical Trial Update: Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) [Phase 1]
A Phase 1 pharmacokinetic study of the JAK inhibitor CP-690,550 (tofacitinib) in pediatric patients with Juvenile Idiopathic Arthritis; the …
-
FDA approval · 2016-06-30FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) to Cordavis Limited, authorizing the continued manufacturing/supply of the p…
-
CLINICAL_TRIALS research · 2016-06-08Clinical Trial Update: Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
This retrospective analysis investigates pulmonary arterial hypertension and related complications in Juvenile Idiopathic Arthritis patients…
-
CLINICAL_TRIALS trial_result · 2016-05-10Clinical Trial Update: "Medikidz Explain JIA Comic Book- Hebrew" [NA]
A completed clinical trial update for the Medikidz Explain JIA Comic Book- Hebrew sponsored by Rabin Medical Center, related to Juvenile Idi…
-
FDA approval · 2016-05-09FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
The FDA approved a supplemental application for Tolmetin sodium submitted by Atland Pharmaceuticals, LLC under ANDA073393.
-
FDA approval · 2016-05-09FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
FDA approved a supplemental application for tolmetin sodium submitted by Atland Pharmaceuticals, LLC.
-
FDA approval · 2016-05-09FDA Approved: INDOMETHACIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for Indomethacin, resulting in updated labeling for the product.
-
FDA approval · 2016-05-09FDA Approved: NAPROXEN — Supplemental Application (Zameer Pharmaceuticals LLC)
FDA approved a supplemental application for Naproxen submitted by Zameer Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2016-05-05Clinical Trial Update: An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study [Phase 3]
Extension long-term study of tocilizumab (RoActemra/Actemra) in patients with polyarticular juvenile idiopathic arthritis who completed the …
-
CLINICAL_TRIALS trial_result · 2016-04-26Clinical Trial Update: Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness [NA]
The study evaluated a web-based cognitive-behavioral therapy program for reducing anxiety and depression symptoms in youths with chronic ill…
-
FDA approval · 2016-04-20FDA Approved: MELOXICAM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for MELOXICAM submitted by Zydus Pharmaceuticals USA Inc. This action constitutes a supplemental…
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA [Phase 4]
This Phase 4 clinical trial update notes the completed study on predictors for safely discontinuing anti-TNF therapy in Juvenile Idiopathic …
-
FDA approval · 2016-04-05FDA Approved: INFLECTRA — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved INFLECTRA (infliximab-dyyb) as a biosimilar to infliximab for multiple autoimmune diseases, expanding access to a biologic ther…
-
CLINICAL_TRIALS trial_result · 2016-03-24Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) [Phase 3]
Phase 3 trial evaluating pharmacokinetics, efficacy, and safety of subcutaneous abatacept in children with active polyarticular juvenile idi…
-
FDA approval · 2016-03-16FDA Approved: CELECOXIB — Original Application (McKesson Corporation dba SKY Packaging)
FDA approved the original Abbreviated New Drug Application for a generic celecoxib product manufactured by McKesson Corporation dba SKY Pack…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use [Phase 3]
Phase 3 compassionate-use trial update for Juvenile Idiopathic Arthritis sponsored by AbbVie. The study is completed and results were posted…
-
CLINICAL_TRIALS trial_result · 2016-01-07Clinical Trial Update: An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis [Phase 3]
Phase 3 extension study for WA19977 in active polyarticular-course juvenile idiopathic arthritis was terminated; results posted in 2016.
-
FDA approval · 2015-12-23FDA Approved: CELECOXIB — Original Application (Torrent Pharmaceuticals Limited)
FDA approved the original application for generic celecoxib by Torrent Pharmaceuticals Limited. This marks approval of a generic version of …